NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/18/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization14.67 mln
Float8.41 mln
Earnings Date11/10/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
7
/ 100
Severely lagging
Debt / Equity
0.03
Debt-free
ROE
-124
Deeply negative
ROA
-108
Deeply negative
Business Description
BioVie Inc. is a US-based medical research company focused on developing treatments for brain disorders and serious liver conditions. Its two main drug candidates are BIV201, targeting fluid buildup caused by liver cirrhosis, and NE3107, which is being tested as a potential treatment for Alzheimer's disease, Parkinson's disease, and long COVID. Founded in 2013 and headquartered in Carson City, Nevada, the company was previously called NanoAntibiotics Inc. before rebranding in 2016.
